PRIME study

PRIME study (A Clinicians’ and Patients’ Survey to examine PreventS for Primary Stroke Prevention)

Background: Stroke and other non-communicable disorders (NCD) such as heart attack, dementia, and diabetes, are major causes of death and disability worldwide. Stroke is up to 90% preventable if the risk factors for stroke are well controlled. PreventS-MD is an electronic patient management system (ePMS) that is built on the Stroke Riskometer™ App - a globally recognised application for assessing risk of stroke. PreventS collects information on stroke risk factors and stroke related outcomes over the previous 12 months, calculates absolute and relative risk of stroke in the next 5 years, and provides patient-tailored recommendations for primary and secondary stroke prevention.

There are 2 parts to this study:

  1. PRIME – International. Involving global partners on PreventS-MD usability and validation.
  2. PRIME – NZ. Involving DHBs and GPs and getting the web-app on MedTech and DHB’s systems.

Aim: (i) to examine clinicians’ as well as patients’ perspectives about the usability of the PreventS app for stroke prevention in clinical practice; (ii) to update the PreventS system based on their feedback.

Materials & Methods: The study involves a survey followed by an interview for the clinicians and  an interview only for patients. The survey and interview will take approximately 30 minutes each to complete.

Prospective outcomes: Optimising the PreventS webapp for the needs of clinicians and patients.

Project leader: Professor Valery Feigin, National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, Auckland, New Zealand.

At present, 55 collaborators representing 24 countries (shown in green) have agreed to participate in the PRIME International study, including NZ.

World map